1. J Visc Surg. 2020 Feb;157(1):13-21. doi: 10.1016/j.jviscsurg.2019.07.012. Epub
 2019 Aug 7.

Bariatric surgery and the perioperative management of type 2 diabetes: Practical 
guidelines.

Galtier F(1), Pattou F(2), Czernichow S(3), Disse E(4), Ritz P(5), Chevallier 
JM(6), Cosson E(7), Valensi P(8), Andreelli F(9), Robert M(10); DIAMS study 
group.

Author information:
(1)CHU Montpellier, Centre d'Investigation Clinique et Département des Maladies 
Endocriniennes, Inserm, CIC 1411, Hôpital St Éloi, 90, avenue Augustin-Fliche, 
34295 Montpellier cedex 05, France. Electronic address: 
f-galtier@chu-montpellier.fr.
(2)University of Lille, CHU Lille Endocrine and Metabolic Surgery, Inserm UMR 
1190 Translational Research for Diabetes, 2, avenue Oscar-Lambret, 59000 Lille, 
France.
(3)Department of Nutrition, Hôpital européen Georges Pompidou (APHP), Centre 
Spécialisé Obésité Ile de France Sud; University Paris Descartes; Inserm UMR 
1153 Epidemiology and Biostatistics Sorbonne Paris Cité Center (METHODS team), 
20, rue Leblanc, 75015 Paris, France.
(4)Fédération Hospitalo-Universitaire DO-IT, Centre Intégré et Spécialisé de 
L'Obésité de Lyon, Université Lyon 1, CRNH-RA, Hospices Civils de Lyon, 165, 
chemin du Grand-Revoyet, 69310 Pierre-Bénite, France.
(5)Centre Intégré Obésité, CHU de Toulouse, Inserm U1027, Université Paul 
Sabatier, route de Narbonne, 31330 Toulouse, France.
(6)Department of Digestive surgery, Hôpital Européen Georges Pompidou (APHP), 
Centre Spécialisé Obésité Ile de France Sud; University Paris 5, 20, rue 
Leblanc, 75015 Paris, France.
(7)Department of endocrinology, diabetology and nutrition, hôpital Jean-Verdier 
(AP-HP), Paris 13 university, Sorbonne Paris Cité, CRNH-IdF, CINFO, avenue du 
14-Juillet, 93140 Bondy, France; UMR U1153 Inserm, U1125 Inra, CNAM, Sorbonne 
Paris Cité, Paris 13 university, 74, rue Marcel-Cachin, 93017 Bobigny cedex, 
France.
(8)Department of endocrinology, diabetology and nutrition, hôpital Jean-Verdier 
(AP-HP), Paris 13 university, Sorbonne Paris Cité, CRNH-IdF, CINFO, avenue du 
14-Juillet, 93140 Bondy, France.
(9)Cardiometabolism and Nutrition Institute (ICAN), Heart and Metabolism 
Department, Pitié-Salpêtrière Hospital (APHP), 47-83, boulevard de l'Hôpital, 
75013 Paris, France; Inserm UMRS U1166 (Eq 6) Nutriomics, UPMC, Pierre et Marie 
Curie Faculty Paris 6, Sorbonne University, 91 et 105, boulevard de l'Hôpital, 
75013 Paris, France.
(10)Inserm UMRS U1166 (Eq 6) Nutriomics, UPMC, Pierre et Marie Curie Faculty 
Paris 6, Sorbonne University, 91 et 105, boulevard de l'Hôpital, 75013 Paris, 
France; Department of Digestive Surgery, Center of Bariatric Surgery, Hospital 
Edouard Herriot, Hospices Civils de Lyon, Lyon, France; Fédération 
Hospitalo-Universitaire DO-IT, Centre Intégré et Spécialisé de L'Obésité de 
Lyon, Université Lyon 1, CRNH-RA, Hospices Civils de Lyon, 165, chemin du 
Grand-Revoyet, 69310 Pierre-Bénite, France.

BACKGROUND: Metabolic surgery is now considered as a therapeutic option in type 
2 diabetes (T2D). However, few data are available regarding perioperative 
management of T2D.
OBJECTIVES: To assess current practice among bariatric teams regarding 
perioperative management of T2D in order to propose guidelines.
METHODS: A two-round Delphi method using online surveys was employed among 
bariatric teams experts (surgeons, diabetologists, anesthetists, nutritionists): 
first round, 63 questions covering 6 topics (characteristics of experts/teams, 
characteristics of patients, operative technique, pre/postoperative management, 
diabetes remission); second round, 44 items needing clarification. They were 
discussed within national congress of corresponding learned societies. Consensus 
was defined as ≥66% agreement.
RESULTS: A total of 170 experts participated. Experts favored gastric bypass to 
achieve remission (76.7%). Screening for retinopathy, cardiac ultrasound, and 
reaching an HbA1c<8% are required in the pre-operative period for 67%, 75.3% and 
56.7% of experts, respectively. After surgery, insulin pump should not be 
stopped, basal insulin should be halved, and bolus insulin should be stopped 
except if severe hyperglycemia. DPP-IV inhibitors and metformin are preferred 
after surgery. Patients should be seen by a diabetologist within one month if on 
oral antidiabetic agents (71.8% of experts), 2 weeks if on injectable treatments 
(77.1% of experts), and immediately after surgery if on insulin pump (93.5% of 
experts). Long-term monitoring of HbA1c is necessary even if diabetes remission 
(100%).
CONCLUSION: Rapid postoperative modifications of blood glucose require a close 
monitoring and a prompt adjustment of diabetes medications.

Copyright © 2019 Elsevier Masson SAS. All rights reserved.

DOI: 10.1016/j.jviscsurg.2019.07.012
PMID: 31401070 [Indexed for MEDLINE]
